Regional Pharmaceutical Contract Manufacturing Market Insights<\/b><\/p>\n
North America is projected to account for the largest share of the pharmaceutical contract manufacturing market, driven by several key factors. The region’s dominance is attributed mainly to the growing population suffering from chronic and infectious diseases, as well as the increasing emphasis on drug discovery and development. The rising demand for biologics and biopharmaceuticals, along with a surge in R&D spending, is significantly contributing to market expansion.<\/p>\n
Additionally, the market is being propelled by heightened research investments from major pharmaceutical companies within the region. The United States, in particular, leads globally in clinical research, representing 29% of all clinical trials worldwide, with 159,403 trials listed as of 2025 (ClinicalTrials.gov). The surge in clinical trials is fueling the need for pharmaceutical contract manufacturing services, including API production, PK\/PD studies, dosage development, and immunogenicity testing, which are essential for establishing drug safety and efficacy.<\/p>\n
In response, leading industry players are broadening their service portfolios. For instance, in August 2024, SGS introduced new specialized pharmaceutical contract manufacturing services in North America. These offerings cover every phase of drug development\u2014from early discovery to Phase I\u2013III trials\u2014and include method transfer, development and validation, PK\/PD bioanalysis, ELISA, multiplex assays, immunogenicity evaluations, and other key bioassays.<\/p>\n
Collectively, these factors are cementing North America’s position as a dominant market for pharmaceutical contract manufacturing, fueled by robust healthcare demand, significant R&D activity, and the growing need for advanced and effective therapies across the region.<\/p>\n
To know more about why North America is leading the market growth in the pharmaceutical contract manufacturing market, get a snapshot of the Pharmaceutical Contract Manufacturing Market Outlook<\/a><\/b><\/p>\n Recent Developmental Activities in the Pharmaceutical Contract Manufacturing Market<\/b><\/p>\n In October 2024, Samsung Biologics<\/b>, a leading global contract development and manufacturing organization (CDMO), announced its largest-ever contract manufacturing deal with a major Asia-based pharmaceutical company. The production for this significant partnership will be carried out at Samsung Biologics’ state-of-the-art biomanufacturing facility in Songdo, South Korea.<\/p>\n<\/li>\n In September 2024, Samsung Biologics<\/b> launched its innovative biologics development platforms S-AfuCHO\u2122 and S-OptiCharge\u2122. S-AfuCHO\u2122 is an innovative cell line platform designed to produce fucosylated antibodies, which demonstrate enhanced antibody-dependent cellular cytotoxicity (ADCC) activity, leading to increased therapeutic efficacy. In parallel, S-OptiCharge\u2122 serves as an upstream process platform capable of modulating a molecule’s charge variant distribution.<\/p>\n<\/li>\n<\/ul>\n Pharmaceutical Contract Manufacturing Overview<\/b><\/p>\n Pharmaceutical contract manufacturing refers to the outsourcing of drug manufacturing processes to a third-party company, commonly called a contract manufacturing organization (CMO). These organizations produce drugs in various dosage forms on behalf of pharmaceutical companies, which may lack manufacturing facilities or choose to outsource for strategic reasons.<\/p>\n Outsourcing to CMOs offers several advantages, including cost savings, increased operational efficiency, and access to specialized technologies and regulatory expertise. Pharmaceutical companies benefit from the flexibility to scale production up or down without heavy capital investment, allowing them to focus more on research, drug development, and commercialization. This model also supports faster time-to-market, especially important in today’s competitive and innovation-driven pharmaceutical landscape.<\/p>\n Report Metrics<\/b><\/p>\n<\/td>\n Details<\/b><\/p>\n<\/td>\n<\/tr>\n Coverage<\/p>\n<\/td>\n Global<\/p>\n<\/td>\n<\/tr>\n Study Period<\/p>\n<\/td>\n 2022\u20132032<\/p>\n<\/td>\n<\/tr>\n Pharmaceutical Contract Manufacturing Market CAGR<\/p>\n<\/td>\n ~9%<\/p>\n<\/td>\n<\/tr>\n Pharmaceutical Contract Manufacturing Market Size by 2032<\/p>\n<\/td>\n ~USD 362 Billion<\/p>\n<\/td>\n<\/tr>\n Key Pharmaceutical Contract Manufacturing Companies<\/p>\n<\/td>\n Lonza, Pfizer Inc., Catalent, Inc., Boehringer Ingelheim International GmbH, Samsung Biologics, WuXi AppTec, Thermo Fisher Scientific Inc., Baxter, Recipharm AB, Merck KGaA, CordenPharma, Siegfried Holding AG, Aenova Group, Almac Group, Alcami Corporation, FUJIFILM Holdings Corporation, Novartis AG, Avery Dennison Corporation, Danaher Corporation, Syntegon Technology GmbH, and others<\/p>\n<\/td>\n<\/tr>\n Pharmaceutical Contract Manufacturing Market Assessment<\/b><\/p>\n Pharmaceutical Contract Manufacturing Market Segmentation<\/b><\/p>\n<\/li>\n Porter’s Five Forces Analysis, Product Profiles, <\/b>Case Studies, KOL’s Views, Analyst’s View<\/b><\/p>\n<\/li>\n<\/ul>\n Which MedTech key players in the pharmaceutical contract manufacturing market are set to emerge as the trendsetter explore @ Pharmaceutical Contract Manufacturing Companies<\/a><\/b><\/p>\n Table of Contents\u00a0<\/b><\/p>\n 1<\/p>\n<\/td>\n Pharmaceutical Contract Manufacturing Market Report Introduction<\/p>\n<\/td>\n<\/tr>\n 2<\/p>\n<\/td>\n Pharmaceutical Contract Manufacturing Market Executive Summary<\/p>\n<\/td>\n<\/tr>\n 3<\/p>\n<\/td>\n Competitive Landscape<\/p>\n<\/td>\n<\/tr>\n 4<\/p>\n<\/td>\n Regulatory Analysis<\/p>\n<\/td>\n<\/tr>\n 5<\/p>\n<\/td>\n Pharmaceutical Contract Manufacturing Market Key Factors Analysis<\/p>\n<\/td>\n<\/tr>\n 6<\/p>\n<\/td>\n Pharmaceutical Contract Manufacturing Market Porter’s Five Forces Analysis<\/p>\n<\/td>\n<\/tr>\n 7<\/p>\n<\/td>\n Pharmaceutical Contract Manufacturing Market Layout<\/p>\n<\/td>\n<\/tr>\n 8<\/p>\n<\/td>\n Pharmaceutical Contract Manufacturing Market Company and Product Profiles<\/p>\n<\/td>\n<\/tr>\n 9<\/p>\n<\/td>\n KOL Views<\/p>\n<\/td>\n<\/tr>\n 10<\/p>\n<\/td>\n Project Approach<\/p>\n<\/td>\n<\/tr>\n 11<\/p>\n<\/td>\n About DelveInsight<\/p>\n<\/td>\n<\/tr>\n 12<\/p>\n<\/td>\n Disclaimer & Contact Us<\/p>\n<\/td>\n<\/tr>\n Interested in knowing the pharmaceutical contract manufacturing market by 2032? Click to get a snapshot of the\u00a0Pharmaceutical Contract Manufacturing Market Trends<\/a><\/b><\/p>\n Related Reports<\/b><\/p>\n Contract Development Manufacturing Organization Market<\/a><\/b><\/p>\n Contract Development Manufacturing Organization Market Insights, Competitive Landscape, and Market Forecast \u2013 2032 <\/b>report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key CDMO companies, including Patheon (Thermo Fisher Scientific), Catalent,Inc, Laboratoire Elaiapharm, The Lubrizol Corporation, Cambrex Corporation, Recipharm (EQT), Merck & Co., Inc, AGC Biologics, Nerpharma S.r.l, Pfizer CenterOne (Pfizer Inc), EMERGENT, Onyx Scientific Limited, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Center for Breakthrough Medicines, and WuXi Biologics<\/b>, among others.<\/p>\n Biopharmaceuticals Contract Manufacturing Market<\/a><\/b><\/p>\n Biopharmaceuticals Contract Manufacturing Market Insights, Competitive Landscape, and Market Forecast \u2013 2032 <\/b>report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key biopharmaceuticals contract manufacturing companies, including Boehringer Ingelheim International GmbH, Lonza, Rentschler Biopharma SE, BINEX Co., Ltd., INCOG BioPharma Service, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Novartis AG, ProBioGen AG, TOYOBO CO., LTD., Samsung Biologics, Thermo Fisher Scientific, Inc., AbbVie, Inc., WuXi Biologics, AGC Biologics, ADMA Biologics, Inc., Baxter BioPharma Solutions (Baxter), iBio., Catalent, Inc., Cambrex Corporation, Pfizer Inc.<\/b>, among others.<\/p>\n Biologics Drug Substance Fill and Finish Manufacturing Market<\/a><\/b><\/p>\n Biologics Drug Substance Fill and Finish Manufacturing Market Insight, Competitive Landscape, and Market Forecast \u2013 2032 <\/b>report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biologics drug substance fill and finish manufacturing companies, including JOINN Biologics, Pharmaron, Symbiosis Pharmaceutical Services, AGC Biologics, INCOG BioPharma Services, CPC, Eurofins Scientific,<\/b> among others.<\/p>\n Biologics Drug Substance Manufacturing Market<\/a><\/b><\/p>\n Biologics Drug Substance Manufacturing Market Insight, Competitive Landscape, and Market Forecast \u2013 2032 <\/b>report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biologics drug substance manufacturing companies, including Lonza, Pfizer Inc., Catalent, Inc., Boehringer Ingelheim International GmbH, Samsung Biologics, WuXi AppTec, Thermo Fisher Scientific Inc., Asahi Kasei Corporation, Recipharm AB, Evotec, Novo Nordisk A\/S, Siegfried Holding AG, Enzene Biosciences Ltd., Forge Biologics, BeiGene LTD., FUJIFILM Holdings Corporation, TOYOBO CO., LTD., AJINOMOTO CO., INC., Biocon, Eurofins Scientific,<\/b> among others.<\/p>\n About\u00a0DelveInsight<\/b><\/p>\n DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n Contact Us\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
<\/b>Shruti Thakur
info@delveinsight.com<\/a>
+14699457679
https:\/\/www.delveinsight.com\/medical-devices<\/a><\/p>\n